tetano
Editor, Senior Moderator
Br J Haematol
. 2023 Nov 15.
doi: 10.1111/bjh.19198. Online ahead of print. Characteristics and outcomes of COVID-19 in Chinese immune thrombocytopenia patients: A prospective cohort study
Yunfei Chen[SUP] 1 2 [/SUP], Jiaying Liu[SUP] 1 2 [/SUP], Shuai Shao[SUP] 1 2 [/SUP], Zhen Song[SUP] 1 2 [/SUP], Yueshen Ma[SUP] 1 2 [/SUP], Yuanyuan Tuo[SUP] 1 2 3 [/SUP], Lijun Fang[SUP] 1 2 [/SUP], Yanmei Xu[SUP] 1 2 [/SUP], Bingqi Xu[SUP] 1 2 [/SUP], Wenjing Gu[SUP] 1 2 [/SUP], Xuan Cao[SUP] 1 2 [/SUP], Jia Chen[SUP] 1 2 [/SUP], Yu Yang[SUP] 1 2 [/SUP], Panjing Wang[SUP] 1 2 [/SUP], Jing Zhang[SUP] 1 2 [/SUP], Yuan Xu[SUP] 1 2 [/SUP], Dandan Yu[SUP] 1 2 [/SUP], Pengxiao Hou[SUP] 1 2 [/SUP], Ke Meng[SUP] 1 2 [/SUP], Zhirong Li[SUP] 1 2 [/SUP], Guanyu Liu[SUP] 1 2 [/SUP], Xinmiao Qu[SUP] 1 2 [/SUP], Lulu Ji[SUP] 1 2 [/SUP], Renchi Yang[SUP] 1 2 [/SUP], Lei Zhang[SUP] 1 2 [/SUP]
Affiliations
The coronavirus disease 2019 (COVID-19) pandemic has a significant impact on the immune system. This is the first and largest study on pre-existing immune thrombocytopenia (ITP) patients infected with COVID-19 in China. We prospectively collected ITP patients infected with COVID-19 enrolled in the National Longitudinal Cohort of Hematological Diseases (NICHE, NCT04645199) and followed up for at least 1 month after infection. One thousand and one hundred forty-eight pre-existing ITP patients were included. Two hundred and twelve (18.5%) patients showed a decrease in the platelet (PLT) count after infection. Forty-seven (4.1%) patients were diagnosed with pneumonia. Risk factors for a decrease in the PLT count included baseline PLT count <50 × 10[SUP]9[/SUP] /L (OR, 1.76; 95% CI, 1.25-2.46; p = 0.001), maintenance therapy including thrombopoietin receptor agonists (TPO-RAs) (OR, 2.27; 95% CI, 1.60-3.21; p < 0.001) and previous splenectomy (OR, 1.98; 95% CI, 1.09-3.61; p = 0.03). Risk factors for pneumonia included age ≥40 years (OR, 2.45; 95% CI, 1.12-5.33; p = 0.02), ≥2 comorbidities (OR, 3.47; 95% CI, 1.63-7.64; p = 0.001), maintenance therapy including TPO-RAs (OR, 2.14; 95% CI, 1.17-3.91; p = 0.01) and immunosuppressants (OR, 3.05; 95% CI, 1.17-7.91; p = 0.02). In this cohort study, we described the characteristics of pre-existing ITP patients infected with COVID-19 and identified several factors associated with poor outcomes.
Keywords: COVID-19; immune thrombocytopenia.
. 2023 Nov 15.
doi: 10.1111/bjh.19198. Online ahead of print. Characteristics and outcomes of COVID-19 in Chinese immune thrombocytopenia patients: A prospective cohort study
Yunfei Chen[SUP] 1 2 [/SUP], Jiaying Liu[SUP] 1 2 [/SUP], Shuai Shao[SUP] 1 2 [/SUP], Zhen Song[SUP] 1 2 [/SUP], Yueshen Ma[SUP] 1 2 [/SUP], Yuanyuan Tuo[SUP] 1 2 3 [/SUP], Lijun Fang[SUP] 1 2 [/SUP], Yanmei Xu[SUP] 1 2 [/SUP], Bingqi Xu[SUP] 1 2 [/SUP], Wenjing Gu[SUP] 1 2 [/SUP], Xuan Cao[SUP] 1 2 [/SUP], Jia Chen[SUP] 1 2 [/SUP], Yu Yang[SUP] 1 2 [/SUP], Panjing Wang[SUP] 1 2 [/SUP], Jing Zhang[SUP] 1 2 [/SUP], Yuan Xu[SUP] 1 2 [/SUP], Dandan Yu[SUP] 1 2 [/SUP], Pengxiao Hou[SUP] 1 2 [/SUP], Ke Meng[SUP] 1 2 [/SUP], Zhirong Li[SUP] 1 2 [/SUP], Guanyu Liu[SUP] 1 2 [/SUP], Xinmiao Qu[SUP] 1 2 [/SUP], Lulu Ji[SUP] 1 2 [/SUP], Renchi Yang[SUP] 1 2 [/SUP], Lei Zhang[SUP] 1 2 [/SUP]
Affiliations
- PMID: 37967471
- DOI: 10.1111/bjh.19198
The coronavirus disease 2019 (COVID-19) pandemic has a significant impact on the immune system. This is the first and largest study on pre-existing immune thrombocytopenia (ITP) patients infected with COVID-19 in China. We prospectively collected ITP patients infected with COVID-19 enrolled in the National Longitudinal Cohort of Hematological Diseases (NICHE, NCT04645199) and followed up for at least 1 month after infection. One thousand and one hundred forty-eight pre-existing ITP patients were included. Two hundred and twelve (18.5%) patients showed a decrease in the platelet (PLT) count after infection. Forty-seven (4.1%) patients were diagnosed with pneumonia. Risk factors for a decrease in the PLT count included baseline PLT count <50 × 10[SUP]9[/SUP] /L (OR, 1.76; 95% CI, 1.25-2.46; p = 0.001), maintenance therapy including thrombopoietin receptor agonists (TPO-RAs) (OR, 2.27; 95% CI, 1.60-3.21; p < 0.001) and previous splenectomy (OR, 1.98; 95% CI, 1.09-3.61; p = 0.03). Risk factors for pneumonia included age ≥40 years (OR, 2.45; 95% CI, 1.12-5.33; p = 0.02), ≥2 comorbidities (OR, 3.47; 95% CI, 1.63-7.64; p = 0.001), maintenance therapy including TPO-RAs (OR, 2.14; 95% CI, 1.17-3.91; p = 0.01) and immunosuppressants (OR, 3.05; 95% CI, 1.17-7.91; p = 0.02). In this cohort study, we described the characteristics of pre-existing ITP patients infected with COVID-19 and identified several factors associated with poor outcomes.
Keywords: COVID-19; immune thrombocytopenia.